Page 6 - Dr Reddy’s Laboratories

DRL launches Avigan for mild Covid-19 infections at Rs 99 a tablet

Drug to be imported from Japan for time being, India manufacturing to start soon

Dr Reddy's launches Avigan (Favipiravir) in India for coronavirus

Dr Reddy's Laboratories Ltd announced the launch of Avigan (Favipiravir) 200 mg tablets in India

Covid-19 drug sales shine even as domestic pharma market slows down

Major therapy areas show decline or low single-digit growth

Dr Reddy's to launch Covid drugs remdesivir and favipiravir in August

Trying to boost acquired Wockhardt portfolio which saw sharp decline in sales during pandemic

Dr Reddy's: Strong Q1 show in spite of disruption lifts sentiment

Normalising US and India sales likely to drive earnings in FY21

Trailing in the value chain: Domestic pharma's unfinished agenda

In the first of a 5-part series, we look at reasons keeping Indian pharma sector from becoming the best globally

Performance may be quite volatile in FY21 due to coronavirus: Dr Reddy's

The company however remains cautiously optimistic of re-calibrating its levers to suit the new business environment, it noted

Covid-19 treatment: Dr Reddy's partners with Fujifilm, GRA for favipiravir

Dr Reddy's will herewith establish a setup for manufacturing drugs of the same quality as Avigan, and utilize GRA's global sales network to supply the manufactured drugs swiftly and in a stable manner

DRL to launch innovator brand of favipiravir, is silent on pricing

Ties up with Fujifilm for exclusive rights over Avigan for Indian market, can sell overseas too

Fujifilm to partner Dr Reddy's to sell Avigan as coronavirus treatment

Japan's Fujifilm Holdings Corp said it was partnering with Dr Reddy's Labs to sell the anti-flu drug Avigan in India and elsewhere to treat Covid-19, the respiratory disease caused by the coronavirus.

Dr Reddy's Lab expects to launch 25 products in US this fiscal year

The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year

Dr Reddy's joins other Indian firms to make Remdesivir under Gilead licence

DRL to receive technology transfer from Gilead and would need to scale up manufacturing and obtain regulatory approvals from 127 countries for marketing the drug

Nifty outlook and stock pick by HDFC Sec: Buy Dr Reddy's Labs, L&T Infotech

Looking at the strong setup on the medium term charts, it would be advisable to buy Nifty around 9,900, for the upside target of 10,300.

From Nestle India to Maruti Suzuki, impact of Covid-19 on earning estimates

Given the huge hit from lockdown, it is not surprising that 44 of the 80 companies have seen sharp cuts ranging 10% to 72%

MARKET WRAP: Sensex ends 114 pts higher, ITC surges 7%; India VIX drops 8%

All that happened in the markets today

Market Ahead, May 20: All you need to know before the opening bell

Reliance Industries will be in focus today as its mega rights issue opens today and closes on June 3

Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit

The plant is one of the company's three units that were served a warning letter in November 2015 for not following the prescribed operational and manufacturing quality standards

Google sees jump in cloud infra use as India stays at home during lockdown

We're pushing limits to bring tech to every user, says Google Cloud India head Karan Bajwa

Diversified model, US outlook to help Dr Reddy's stock trade better

The company has multiple growth engines given its focus on India/emerging markets and limited competition products in the US

Wockhardt tanks 5% after it sells domestic branded ops to Dr Reddy's Labs

The deal, which could fetch a consideration amount of Rs 1,850 crore, is expected to close in the first quarter of financial year 2020-21, Wockhardt added.